Biodesix Inc
BDSX- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001439725
In the last 90 days, Biodesix Inc insiders filed 1 open-market purchase and 0 sales; 60 institutions reported holding it in 13F filings for Q3 2026, worth $145.3M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:49 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $35.3M (39.8% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Jan 10, 2025 | Mar 1, 2024 | Mar 6, 2023 | Feb 14, 2022 |
| Revenue | $88.5M | $71.3M | $49.1M | $38.2M | $54.5M |
| Operating expenses | $116.4M | $105.8M | $90.4M | $88.8M | $95.4M |
| Research and development | $12.0M | $9.56M | $9.99M | $13.1M | $12.8M |
| Selling, general and administrative | $87.5M | $80.5M | $67.4M | $61.5M | $50.5M |
| Operating income | -$27.9M | -$34.5M | -$41.3M | -$50.6M | -$40.9M |
| Interest expense | $7.72M | $8.26M | $9.54M | $8.07M | $4.51M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$35.3M | -$42.9M | -$52.1M | -$65.4M | -$43.2M |
| EPS, basic | $-4.67 | $-0.33 | $-0.64 | $-1.55 | – |
| EPS, diluted | $-4.67 | $-0.33 | $-0.64 | $-1.55 | – |
| Weighted shares, basic | 7.55M | 129.7M | 82.1M | 42.1M | – |
| Weighted shares, diluted | 7.55M | 129.7M | 82.1M | 42.1M | – |
| Margins and growth | |||||
| Operating margin | -31.5% | -48.4% | -84.2% | -132.4% | -75.1% |
| Net margin | -39.8% | -60.2% | -106.2% | -171.3% | -79.2% |
| Revenue growth, year over year | +24.1% | +45.3% | +28.5% | −29.9% | +19.6% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Jan 10, 2025 | Mar 1, 2024 | Mar 6, 2023 | Feb 14, 2022 |
| Cash and equivalents | $19.0M | $26.2M | $26.3M | $43.1M | $32.7M |
| Accounts receivable | $9.04M | $8.60M | $7.68M | $5.07M | $3.66M |
| Total current assets | $32.5M | $39.5M | $39.7M | $53.3M | $43.6M |
| Property, plant and equipment | $24.8M | $27.8M | $27.9M | $5.85M | $4.18M |
| Goodwill | $15.0M | $15.0M | $15.0M | $15.0M | $15.0M |
| Intangible assets | $3.88M | $5.87M | $7.91M | $9.80M | $11.6M |
| Total assets | $87.5M | $97.2M | $99.1M | $92.9M | $76.1M |
| Accounts payable | $3.08M | $2.19M | $2.93M | $1.69M | $1.66M |
| Total current liabilities | $17.4M | $14.3M | $33.4M | $22.8M | $29.0M |
| Long-term debt | $50.0M | $40.0M | $40.1M | $30.1M | $10.1M |
| Total liabilities | $89.9M | $76.4M | $94.5M | $72.3M | $56.4M |
| Shareholders' equity | -$2.46M | $20.9M | $4.58M | $20.6M | $19.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Jan 10, 2025 | Mar 1, 2024 | Mar 6, 2023 | Feb 14, 2022 |
| Operating cash flow | -$23.3M | -$48.6M | -$22.9M | -$45.0M | -$28.2M |
| Capital expenditures | $259.0K | $3.23M | $22.9M | $3.30M | $2.24M |
| Free cash flow | -$23.5M | -$51.9M | -$45.8M | -$48.3M | -$30.5M |
| Depreciation and amortization | $5.67M | $5.77M | $3.33M | $3.60M | $3.18M |
| Stock-based compensation | $4.14M | $6.64M | $5.37M | $5.96M | $4.94M |
| Investing cash flow | -$403.0K | -$3.44M | -$23.1M | -$3.53M | -$2.55M |
| Financing cash flow | $16.4M | $52.0M | $29.1M | $58.9M | $1.26M |
| Net change in cash | -$7.26M | -$39.0K | -$16.8M | $10.4M | -$29.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 4.7% | 9.3% | 10.9% | 15.6% | 9.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 11.1M | +39.4% | SEC |
| Jul 30, 2026 | 10.6M | −92.8% | SEC |
| Apr 29, 2026 | 10.1M | −93.1% | SEC |
| Feb 20, 2026 | 9.86M | −93.2% | SEC |
| Oct 28, 2025 | 7.96M | −94.5% | SEC |
| Jul 31, 2025 | 146.6M | +1.0% | SEC |
| May 7, 2025 | 146.6M | +27.8% | SEC |
| Feb 24, 2025 | 146.0M | +50.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-20 in Q3 2025.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.